Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. The bacterium usually enters the body through the mouth by the ingestion of contaminated food or water, penetrates the intestinal wall, and multiplies in lymphoid tissue. It then enters the bloodstream and causes bacteremia. People who drink contaminated water or eat food washed in contaminated water can develop typhoid fever. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.
Currently there are three typhoid vaccines recommended by the World Health organization (WHO) for use which include:
- Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age
- Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above, and
- Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age
Market Dynamics
Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period. For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, Center for Disease Control and Prevention and Zimbabwe’s Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe’s capital with new typhoid conjugate vaccine (TCV). At least 12.4 million children worldwide are categorized as ‘zero-dose’, living in missed communities that cannot access many essential services, including health care.
Key features of the study:
- This report provides an in-depth analysis of the global typhoid fever vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global typhoid fever vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global typhoid fever vaccines market
Detailed Segmentation:
- Global Typhoid Fever Vaccines Market, By Vaccine Type:
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
- Global Typhoid Fever Vaccines Market, By Route of Administration:
- Global Typhoid Fever Vaccines Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- GlaxoSmithKline Plc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi SA
- Bharat Biotech
- Bio-Med Pvt. Ltd.
- PT Bio Farma
- PaxVax, Inc.
- Shanghai Institute of Biological Products Co., Ltd.
- Prokarium
“*” marked represents similar segmentation in other categories in the respective section.
